167 related articles for article (PubMed ID: 24957381)
1. Predictors of statin compliance after switching from branded to generic agents among managed-care beneficiaries.
Romanelli RJ; Segal JB
J Gen Intern Med; 2014 Oct; 29(10):1372-8. PubMed ID: 24957381
[TBL] [Abstract][Full Text] [Related]
2. Compliance after switching from branded to generic statins.
Romanelli RJ; Jukes T; Segal JB
Pharmacoepidemiol Drug Saf; 2014 Oct; 23(10):1093-100. PubMed ID: 24817435
[TBL] [Abstract][Full Text] [Related]
3. Capsule commentary on Romanelli et al., predictors of statin compliance after switching from branded to generic agents among managed-care beneficiaries.
Pathak H
J Gen Intern Med; 2014 Oct; 29(10):1391. PubMed ID: 25103124
[No Abstract] [Full Text] [Related]
4. Generic and therapeutic statin switches and disruptions in therapy.
Chapman RH; Benner JS; Girase P; Benigno M; Axelsen K; Liu LZ; Nichol MB
Curr Med Res Opin; 2009 May; 25(5):1247-60. PubMed ID: 19344292
[TBL] [Abstract][Full Text] [Related]
5. Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study.
Desai RJ; Sarpatwari A; Dejene S; Khan NF; Lii J; Rogers JR; Dutcher SK; Raofi S; Bohn J; Connolly J; Fischer MA; Kesselheim AS; Gagne JJ
BMJ; 2018 Apr; 361():k1180. PubMed ID: 29615391
[TBL] [Abstract][Full Text] [Related]
6. Evidence of sample use among new users of statins: implications for pharmacoepidemiology.
Li X; Stürmer T; Brookhart MA
Med Care; 2014 Sep; 52(9):773-80. PubMed ID: 24984210
[TBL] [Abstract][Full Text] [Related]
7. Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients.
Kwong WJ; Kamat S; Fang C
Ann Pharmacother; 2012 Dec; 46(12):1609-16. PubMed ID: 23150608
[TBL] [Abstract][Full Text] [Related]
8. The changing patterns of dispensing branded and generic drugs for the treatment of gastroesophageal reflux disease between 2006 and 2011 in Japan: a retrospective cohort study.
Murata K; Hinotsu S; Hamada S; Ezoe Y; Muto M; Kawakami K
BMC Health Serv Res; 2015 Feb; 15():76. PubMed ID: 25885571
[TBL] [Abstract][Full Text] [Related]
9. Switching, Persistence and Adherence to Statin Therapy: a Retrospective Cohort Study Using the Australian National Pharmacy Data.
Talic S; Marquina C; Ofori-Asenso R; Petrova M; Liew D; Owen AJ; Lybrand S; Thomson D; Ilomaki J; Zomer E; Ademi Z
Cardiovasc Drugs Ther; 2022 Oct; 36(5):867-877. PubMed ID: 34097194
[TBL] [Abstract][Full Text] [Related]
10. Patient adherence to generic versus brand statin therapy after acute myocardial infarction: Insights from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines Registry.
O'Brien EC; McCoy LA; Thomas L; Peterson ED; Wang TY
Am Heart J; 2015 Jul; 170(1):55-61. PubMed ID: 26093864
[TBL] [Abstract][Full Text] [Related]
11. What is associated with increased side effects and lower perceived efficacy following switching to a generic medicine? A New Zealand cross-sectional patient survey.
MacKrill K; Petrie KJ
BMJ Open; 2018 Oct; 8(10):e023667. PubMed ID: 30341138
[TBL] [Abstract][Full Text] [Related]
12. The need for a systematic approach to statin switching: an analysis of real-world experience.
Kakavas PW; McManus JL; Wolfe TA; Guidry T; Flores DN; Ter Riet LB; Glover JJ; Sell H
J Cardiovasc Nurs; 2013; 28(6):565-72. PubMed ID: 23064180
[TBL] [Abstract][Full Text] [Related]
13. Generic alendronate use among Medicare beneficiaries: are Part D data complete?
Yun H; Curtis JR; Saag K; Kilgore M; Muntner P; Smith W; Matthews R; Wright N; Morrisey MA; Delzell E
Pharmacoepidemiol Drug Saf; 2013 Jan; 22(1):55-63. PubMed ID: 23135758
[TBL] [Abstract][Full Text] [Related]
14. Primary nonadherence to statin medications in a managed care organization.
Cheetham TC; Niu F; Green K; Scott RD; Derose SF; Vansomphone SS; Shin J; Tunceli K; Reynolds K
J Manag Care Pharm; 2013 Jun; 19(5):367-73. PubMed ID: 23697474
[TBL] [Abstract][Full Text] [Related]
15. Impact of out-of-pocket expenses on discontinuation of statin therapy: a cohort study in Finland.
Helin-Salmivaara A; Korhonen MJ; Alanen T; Huupponen R
J Clin Pharm Ther; 2012 Feb; 37(1):58-64. PubMed ID: 21410736
[TBL] [Abstract][Full Text] [Related]
16. LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice.
Rublee DA; Burke JP
Postgrad Med; 2010 Mar; 122(2):16-24. PubMed ID: 20203452
[TBL] [Abstract][Full Text] [Related]
17. Patient co-payment and adherence to statins: a review and case studies.
Simoens S; Sinnaeve PR
Cardiovasc Drugs Ther; 2014 Feb; 28(1):99-109. PubMed ID: 24150747
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic dose assessment of patient switching from atorvastatin to simvastatin.
Hess G; Sanders KN; Hill J; Liu LZ
Am J Manag Care; 2007 Jun; 13 Suppl 3():S80-5. PubMed ID: 17596116
[TBL] [Abstract][Full Text] [Related]
19. Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective study.
Hussein MA; Chapman RH; Benner JS; Tang SS; Solomon HA; Joyce A; Foody JM
Am J Cardiovasc Drugs; 2010; 10(3):193-202. PubMed ID: 20387911
[TBL] [Abstract][Full Text] [Related]
20. Lowering copayments: impact of simvastatin patent expiration on patient adherence.
Sedjo RL; Cox ER
Am J Manag Care; 2008 Dec; 14(12):813-8. PubMed ID: 19067498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
